{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342402","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2026-08-10T20:12:21+00:00","discovered_at":"2026-08-10T20:14:00.258144+00:00","generated_at":"2026-08-10T20:14:23.786645+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nkarta Q2 2026: cash $243.2M, net loss $40.4M; NKX019 trials advance","bullets":["Cash, equivalents, restricted cash and investments $243.2M as of June 30, 2026; expected to fund operations into 2029.","Q2 2026 net loss $40.4M ($0.54 per share); R&D expense $29.0M, G&A expense $14.1M.","Enrollment continues across Ntrust-1 and Ntrust-2 at 4B cells/dose (12B total) in all autoimmune indications.","Outpatient dosing underway at community sites after FDA agreement; initial Ntrust data expected at 2026 medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342402","json":"https://secwatch.observer/filing/0001193125-26-342402.json","markdown":"https://secwatch.observer/filing/0001193125-26-342402.md","text":"https://secwatch.observer/filing/0001193125-26-342402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/0001193125-26-342402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000119312526342402/nktx-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:14:23.786645+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}